Subconjunctival Rituximab Administration for the Treatment of Scleritis.
Ocul Immunol Inflamm
; 30(6): 1309-1311, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-35171758
ABSTRACT
PURPOSE:
Scleritis is a sight-threatening inflammation, which is commonly accompanied by severe complications. Aggressive systemic immunosuppressive treatment, which is frequently needed, can be associated with serious complications, and might therefore be (temporarily) contraindicated.METHODS:
We report on the outcomes of three patients with severe, active, non-infectious scleritis, refractory or intolerant to systemic treatment, who received subconjunctival rituximab (RTX) injections. A dose of 2.5 to 7.5 mg was administered after topical anesthesia, and follow-up varied from 8 to 10 months.RESULTS:
Subconjunctival RTX showed minimal to no effect on subjective symptoms, clinical features and/or ultrasound images. No serious adverse effects occurred.CONCLUSION:
Further studies are needed to assess the effect of local administration of RTX in scleritis, but our limited observation is not promising.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esclerite
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article